Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness

Biological Psychiatry

Volumn 46, Issue 10, 1999, Pages 1328-1351

  Manji, Husseini K ^a   Lenox, Robert H ^b  

^a Lab of Molecular Pathophysiology   (United States)

^b Molec Neuropsychopharmacology Prog   (United States)

Author keywords

AP 1; Lithium; Manic depressive; MARCKS; Protein kinase C; Valproate

Indexed keywords

ANTIESTROGEN; CARBAMAZEPINE; CYTIDINE PHOSPHATE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LITHIUM CHLORIDE; MARCKS PROTEIN; MORPHINE; PHENYTOIN; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID; VERAPAMIL; ENZYME ACTIVATOR; GLYCOGEN SYNTHASE KINASE 3; PROTEIN KINASE (CALCIUM,CALMODULIN); TRANQUILIZER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HIPPOCAMPUS; HUMAN; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; ANIMAL; AWARDS AND PRIZES; BINDING COMPETITION; BIPOLAR DISORDER; BRAIN; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; RESEARCH; REVIEW; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANTIMANIC AGENTS; AWARDS AND PRIZES; BINDING, COMPETITIVE; BIPOLAR DISORDER; BLOTTING, WESTERN; BRAIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; MALE; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RESEARCH; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 0033570745     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00235-8     Document Type: Review

References (192)

1. Aderem A. The MARCKS brothers A family of protein kinase C substrates . Cell. 71:1992;713-716.
2. Ahrens B., Muller-Oerlinghausen B., Schou M., et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affective Disord. 33:1995;67-75.
3. Allison J.H., Stewart M.A. Reduced brain inositol in lithium treated rats. Nature. 233:1971;267-268.
4. Apparsundaram S., Schroeter S., Giovanetti E., Blakely R.D. Acute regulation of norepinephrine transport II. PKC-modulated surface expression of human norepinephrine transporter proteins . J Pharmacol Exp Ther. 287:1998;744-751.
5. Atack J.R., Prior A.M., Griffith D., Ragan C.I. Characterization of the effects of lithium on phosphatidylinositol (PI) cycle activity in human muscarinic m1 receptor-transfected CHO cells. Br J Pharmacol. 110:1993;809-815.
6. Atkins C.M., Chen S.J., Klann E., Sweatt J.D. Increased phosphorylation of myelin basic protein during hippocampal long-term potentiation. J Neurochem. 68:1997;1960-1967.
7. Baldessarini R.J., Tondo L., Faedda G.L., et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry. 57:1996;441-448.
8. Baraban J.M., Worley P.F., Synder S.H. Second messenger systems and psychoactive drug focus on the phosphoinositide system and lithium. Am J Psychiatry. 146:1989;1251-1260.
9. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Manji HK (in press): A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Arch Gen Psychiatry.
10. Ben-Schlomo H., Sigmund O., Stabel S., Reiss N., Naor Z. Preferential release of catecholamine from permeabilized PC12 cells by α and β type protein kinase C subspecies. Biochem J. 280:1991;65-69.
11. Berridge M.J., Downes C.P., Hanley M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J. 206:1982;587-595.
12. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium A unifying hypothesis . Cell. 59:1989;411-419.
13. Bevilacqua J.A., Downes C.P., Lowenstein P.R. Visualization of agonist-stimulated inositol phospholipid turnover in individual neurons of the rat cerebral cortex and hippocampus. Neuroscience. 60:1994;945-958.
14. Billah M.M., Anthes J.C. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J. 269:1990;281-291.
15. Blackshear P.J. The MARCKS family of cellular protein kinase C substrates. J Biol Chem. 268:1993;1501-1504.
16. Blakely R.D., Ramamoorthy S., Schroeter S., Qian Y., Apparsundaram S., Galli A., DeFelice L.J. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry. 44:1998;169-178.
17. Bojes H.K., Thurman R.G. Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo. Toxicol Appl Pharmacol. 126:1994;233-239.
18. Borner C., Guadagno S.N., Fabbro D., Weinstein I. Expression of four protein kinase C isoforms in rat fibroblasts. Distinct subcellular distribution and regulation by calcium and phorbol esters. J Bio Chem. 267:1992;12892-12899.
19. Bourne HR, Nicoll R (1993): Molecular machines integrate coincident synaptic signals. Cell 72(suppl):65-75.
20. Bowden CL (in press): Valproate in mania. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar Medications: Mechanisms of Action. Washington, DC: American Psychiatric Press.
21. Bowden C.L., Brugger A.M., Swann A.C., et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA. 271:1994;918-924.
22. Boyle W.J., Smeal T., Defize L.H., Angel P., Woodgett J.R., Karin M., Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell. 64:1991;573-584.
23. Brami B.A., Leli U., Hauser G. Influence of lithium on second messenger accumulation in NG108-15 cells. Biochem Biophys Res Commun. 174:1991;606-612.
24. Brami B.A., Leli U., Hauser G. Elevated phosphatidyl-CMP is not the source of diacylglycerol accumulation induced by lithium in NG108-15 cells. J Neurochem. 60:1993;1137-1142.
25. Casebolt T.L., Jope R.S. Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. Biol Psychiatry. 29:1991;233-243.
26. Catt K.J., Balla T. Phosphoinositide metabolism and hormone action. Annu Rev Med. 40:1989;487-509.
27. Chang M.C., Grange E., Rabin O., Bell J.M., Allen D.D., Rapoport S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett. 220:1996;171-174.
28. Chen G., Hawver D., Wright C., Potter W.Z., Manji H.K. Attenuation of adenylyl cyclases by carbamazepine in vitro. J Neurochem. 67:1996;2079-2086.
29. Chen G., Huang L.D., Jiang Y., Manji H.K. The mood stabilizing agent Valproate inhibits the activity of Glycogen Synthase Kinase 3. J Neurochem. 72:1999;1327-1330.
30. Chen G., Manji H.K., Hawver D.B., et al. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem. 63:1994;2361-2364.
31. Chen G., Yuan P., Hawver D., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
32. Chen G., Yuan P.X., Jiang Y., Huang L.D., Manji H.K. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem. 70:1998;1768-1771.
33. Chen G., Yuan P.X., Jiang Y., Huang L.D., Manji H.K. Valproate robustly enhances AP-1 mediated gene expression. Mol Brain Res. 64:1999;52-58.
34. Chen G., Zeng W., Yuan P., Huang L., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 72:1999;879-882.
35. Cheng A.L., Chuang S.E., Fine R.L., Yeh K.H., Liao C.M., Lay J.D., Chen D.S. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol. 55:1998;523-531.
36. Chou J.C. Recent advances in treatment of acute mania. J Clin Psychopharmacol. 11:1991;3-21.
37. Chuang D.M. Neurotransmitter receptors and phosphoinositide turnover. Annu Rev Pharmacol Toxicol. 29:1989;71-110.
38. Cooper T.B., Bergner P.E., Simpson G.M. The 24 hour serum lithium level as a pronosticator of dosage requirements. Am J Psychiatry. 130:1973;601-603.
39. Daigen A., Aakiyama K., Otsuki S. Long-lasting change in the membrane-associated protein kinase C activity in the hippocampal kindled rat. Brain Res. 545:1991;131-136.
40. Depue RA, Karuss SP, Spoont MR (1987): A two-dimensional threshold model of seasonal bipolar affective disorder. In: Magnusson D, Ohman A, editors. Psychopathology: An Interactional Perspective.Orlando, FL: Academic Press, 95-123.
41. Downes C.P., Stone M.A. Lithium-induced reduction in intracellular inositol supply in cholinergically stimulated parotid gland. Biochem J. 234:1986;199-204.
42. Drummond A.H., Raeburn C.A. The interaction of lithium with thyrotropin releasing hormone-stimulated lipid metabolism in GH3 pituitary tumor cells. Biochem J. 224:1984;129-136.
43. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
44. Dwivedi Y., Pandey G.N. Administration of dexmethasone up-regulates protein kinase C activity and the expression of and protein kinase C isozymes in the rat brain. J Neurochem. 72:1999;380-387.
45. Erusalimsky J.D., Brooks S.F., Herget T., et al. Molecular cloning and characterization of the acidic 80-kDa protein kinase C substrate from rat brain. J Biol Chem. 266:1991;7073-7080.
46. Exton J.H. Signaling through phosphatidylcholine breakdown. J Biol Chem. 265:1990;1-4.
47. Faedda G.L., Tondo L., Baldessarini R.J., et al. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry. 50:1993;448-455.
48. Fisher S.K., Heacock A.M., Agranoff B.W. Inositol lipids and signal transduction in the nervous system An update . J Neurochem. 58:1992;18-38.
49. Freidman E., Hoau Y.W., Levinson D., Connell T.A., Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 33:1993;520-525.
50. Frye M.A., Altshuler L.L., Szuba M.P., et al. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry. 57:1996;17-21.
51. Gani D., Downes C.P., Batty I., Bramham J. Lithium and myo-inositol homeostasis. Biochem Biophys Acta. 1177:1993;253-269.
52. Giambalvo C.T. Protein kinase C and dopamine transport - 1. Effects of amphetamine in vivo. Neuropharmacology. 31:1992;1201-1210.
53. Giambalvo C.T. Protein kinase C and dopamine transport - 2. Effects of amphetamine in vitro. Neuropharmacology. 31:1992;1211-1222.
54. Glanville N.T., Byres D.M., Cook H.W., Spence M.W., Palmer F.B. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochem Biophys Acta. 1004:1989;169-179.
55. Gnegy M.E., Hong P., Ferrell S.T. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res. 20:1993;289-298.
56. Godfrey P.P., McClue S.J., White A.M., Wood A.J., Grahame-Smith D.G. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J. 258:1989;621-624.
57. Goodnight J., Mischak H., Kolch W., Mushinski J.F. Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. J Biol Chem. 270:1995;9991-10001.
58. Goodwin F.K., Ghaemi S.N. Bipolar Disorder State of the art . Dialogues Clin Neurosci. 1:1999;41-51.
59. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. 1990;Oxford University Press, New York.
60. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J Clin Psychiatry. 54:1993;405-418.
61. Guitart X., Nestler E.J. Chronic administration of lithium or other antidepressants increases levels of DARPP-32 in rat frontal cortex. J Neurochem. 59:1992;1164-1167.
62. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. J Biol Chem. 255:1980;10896-10901.
63. Hannun Y.A., Bell R.M. Rat-brain protein kinase-C-kinetic-analysis of substrate dependence, allosteric regulation and autophosphorylation. J Biol Chem. 265:1990;2962-2972.
64. Haskett R.F. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry. 142:1985;911-916.
65. Hedgepeth C.M., Conrad L.J., Zhang J., Huang H.C., Lee V.M., Klein P.S. Activation of the Wnt signaling pathway A molecular mechanism for lithium action . Dev Biol. 185:1997;82-91.
66. Henn FA, McKinney WT (1987): Animal Models in Psychiatry. In: Meltzer HY, editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 687-695.
67. Hoelting T., Duh Q.Y., Clark O.H., Herfarth C. Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C. Cancer Lett. 100:1996;89-93.
68. Horgan K., Cooke E., Hallett M.B., Mansel R.E. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol. 35:1986;4463-4465.
69. Hsiao J.K., Argen H., Bartko J.J., Rudorfer M.V., Linnoila M., Potter W.Z. Monoamine neurotransmitter interactions and the prediction of antidepressant response. Arch Gen Psychiatry. 44:1987;1078-1083.
70. Hsiao J.K., Colison J., Bartko J.J., Doran A.R., Konicki P.E., Potter W.Z., Pickar D. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry. 50:1993;606-614.
71. Huang F.L., Yoshida Y., Cunha-Melo J.R., Beaven M.A., Huang K.P. Differential down-regulation of protein kinase C isozymes. J Biol Chem. 264:1989;4238-4243.
72. Huang K.P. The mechanism of protein kinase C activation. Trends Neurosci. 12:1989;425-432.
73. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev. 47:1995;133-178.
74. Hyman S.E., Nestler E.J. Initiation and adaptation A paradigm for understanding psychotropic drug action . Am J Psychiatry. 153:1996;151-162.
75. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway forms a complex with GSK-3β and β-catenin. Embo J. 17:1997;1371-1384.
76. Ikonomov O, Manji HK (in press): Molecular mechanisms underlying mood-stabilization in manic-depressive illness: The phenotype challenge. Am J Psychiatry.
77. Isakov N., McMahon P., Altman A. Selective post-transcription down-regulation of protein kinase C isoenzymes in Leukemic T cells chronically treated with phorbol ester. J Biol Chem. 265:1990;2091-2097.
78. Iwata S.I., Hewlett G.H., Ferrell S.T., Kantor L., Gnegy M.E. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J Pharmacol Exp Ther. 283:1997;1445-1452.
79. Iwata S., Hewlett G.H., Gnegy M.E. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptomosomes. Synapse. 26:1997;281-291.
80. Jackson S. Regulating transcription factor activity by phosphorylation. Trends Cell Biol. 2:1992;104-108.
81. Jamison K.R. Suicide and bipolar disorders. Ann N Y Acad Sci. 487:1986;301-315.
82. Janowsky D.S., El-Yousef M.K., Davis J.M., Sekerke H.J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 2:1972;632-635.
83. Jensen J.B., Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol. 7:1997;173-179.
84. Jope R.S. Anti-bipolar therapy Mechanism of action of lithium . Mol Psychiatry. 4:1999;117-128.
85. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol Psychiatry. 4:1999;21-25.
86. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem Pharmacol. 77:1994;429-441.
87. Kandel E.R. A new intellectual framework for psychiatry. Am J Psychiatry. 155:1998;457-469.
88. Kantor L., Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther. 284:1998;592-598.
89. Karin M., Smeal T. Control of transcription factors by signal transduction pathways The beginning of the end . Trends Biochem Sci. 17:1992;418-422.
90. Keck P.E. Jr, McElroy S.L., Nemeroff C.B. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci. 4:1992;395-405.
91. Kishimoto A., Mikawa K., Hashimoto K., et al. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J Biol Chem. 264:1989;4088-4092.
92. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 93:1996;8455-8459.
93. Kramlinger K.G., Post R.M. The addition of lithium to carbamazepine Antidepressant efficacy in treatment-resistant mania . Arch Gen Psychiatry. 46:1989;794-800.
94. Kuroda T., Nishizuka Y. Limited proteolysis of protein kinase C subspecies by calcium-dependent neural protease (calpain). J Biol Chem. 264:1989;4088-4092.
95. Lee H.J., Hammond D.N., Large T.H., Roback J.D., Sim J.A., Brown D.A., Otten U.H., Wainer B.H. Neuronal properties and trophic activities of immortalized hippocampal cells from embryonic and young adult mice. J Neurosci. 10:1990;1779-1787.
96. Leli U, Hauser G (1992): Lithium modifies diacylglycerol levels and protein kinase C in neuroblastoma cells. Abstracts of the 8th International Conference on Second Messengers and Phosphoproteins. Z187F.
97. Leli U., Shea T.B., Cataldo A., et al. Differential expression and subcellular localization of protein kinase C alpha, beta, gamma, delta, and epsilon isoforms in SH-SY5Y neuroblastoma cells Modifications during differentiation . J Neurochem. 60:1993;289-298.
98. Lenox R.H. Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. Adv Exp Med Biol. 221:1987;515-530.
99. Lenox RH, Manji HK (1998): Lithium. In: Nemeroff CB, Schatzber AF, editors. American Psychiatric Press Textbook of Psychopharmacology, 2nd ed. Washington, DC: American Psychiatric Press, 379-430.
100. Lenox R.H., Watson D.G.J.P., Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570:1992;333-340.
101. Lenox R.H., Watson D.G. Lithium and the brain A psychopharmacological strategy to a molecular basis for manic depressive illness . Clin Chem. 40:1994;309-314.
102. Li X., Jope R.S. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells. J Neurochem. 65:1995;2500-2508.
103. Lin A., Smeal T., Binetruy B., Deng T., Chambard J.C., Karin M. Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res. 28:1993;255-260.
104. Linder D., Gschwendt M., Marks F. Phorbol ester-induced down-regulation of the 80-kDa myristoylated alanine-rich C-kinase substrate-related protein in Swiss 3T3 fibroblasts. J Biol Chem. 267:1992;24-26.
105. Loscher W. Valproate A reappraisal of its pharmacodynamic properties and mechanisms of action . Prog Neurobiol. 58:1999;31-59.
106. Lucas F.R., Salinas P.C. WNT-7a induces axonal remodeling and increases Synapsin I levels in cerebellar neurons. Dev Biol. 192:1997;31-44.
107. Lyon M (1991): Animal models for the symptoms of mania. In: Bolton A, Baker G, Martin-Iverson M, editors. Neuromethods, Vol. 18: Animal Models in Psychiatry I. Totowa, NJ: Humana Press Inc.
108. MacDonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia. 36:(suppl 2):1995;S2-S12.
109. Mandell A.J., Knapp S., Ehlers C., et al. The stability of constrained randomness Lithium prophylaxis at several neurobiological levels . Post R.M., Ballenger J.C. Neurobiology of Mood Disorders. 1984;744-776 Williams & Wilkins, Baltimore.
110. Manji HK (1992): G proteins: implications for psychiatry. Am J Psychiatry 149:746-460.
111. Manji H.K., Etcheberrigaray R., Chen G., Olds J.L. Lithium decreases membrane-associated Protein kinase C in hippocampus Selectivity for the a isozyme . J Neurochem. 61:1993;2303-2310.
112. Manji H.K., Chen G., Hsiao J.K., et al. Regulation of signal transduction pathways by mood-stabilizing agents implications for the delayed onset of therapeutic efficacy . J Clin Psychiatry. 57:(suppl 13):1996;34-46.
113. Manji H.K., Lenox R.H. Long-term action of lithium A role for transcriptional and posttranscriptional factors regulated by protein kinase C . Synapse. 16:1994;11-28.
114. Manji H.K., Lenox R.H. Lithium A unique cation in biology and medicine . Neuropsychopharmacology. 19:1998;161-240.
115. Manji HK, Moore GJ, Chen G (in press): Lithium at 50: Have the neuroprotective properties of this unique cation been overlooked? Biol Psychiatry.
116. Manji H.K., Potter W.Z., Lenox R.H. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry. 52:1995;531-543.
117. Matthies H.J.G., Palfrey H.C., Hirning L.D., Miller R.J. Down regulation of Protein kinase C in neuronal cells Effects on neurotransmitter release . J Neuroscience. 7:1987;1198-1206.
118. McElroy S.L., Keck P.E., Stanton S.P., et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 57:1996;142-146.
119. McIlroy B.K., Walters J.D., Blackshear P.J., Johnson J.D. Phosphorylation-dependent binding of a synthetic MARCKS peptide to calmodulin. J Biol Chem. 266:1991;4959-4966.
120. McNamara R.K., Stumpo D.J., Morel L.M., Lewis M.H., Wakeland E.K., Blackshear P.J., Lenox R.H. Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice Transgenic rescue and interactions with gene background . Proc Natl Acad Sci USA. 95:1998;14517-14522.
121. Meltzer HY (1992): The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 17(suppl):22-29.
122. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK (in press): Temporal dissociation between lithium-induced CNS myo-inositol changes and clinical response in manic-depressive illness. Am J Psychiatry.
123. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system Involvement of the inducible proto-oncogenes Fos and Jun . Annu Rev Neurosci. 14:1991;421-451.
124. Mork A., Geisler A., Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol. 71:(suppl 1):1992;4-17.
125. Muller-Oerlinghausen B., Ahrens B., Grof E., Grof P., Lenz G., Schou M., Simhandl C., Thau K., Volk J., Wolf R., et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand. 86:1992;218-222.
126. Nahorski S.R., Ragan C.I., Challiss R.A.J. Lithium and the phosphoinositide cycle An example of uncompetitive inhibition and its pharmacological consequences . Trends Pharmacol Sci. 12:1991;297-303.
127. Nahorski S.R., Jenkinson S., Challis R.A. Disruption of phosphoinositide signalling by lithium. Biochem Soc Trans. 20:1992;430-434.
128. Nalepa I. The effect of psychotropic drugs on the interaction of protein kinase C with second messenger systems in the rat cerebral cortex. Pol J Pharmacol. 45:(5-6):1993;521-532.
129. Nalepa I. The effect of psychotropic drugs on the interaction of protein kinase C with second messenger systems in the rat cerebral cortex. Pol J Pharmacol. 46:(1-2):1994;1-14.
130. Nemeroff C.B. Handbook of Clinical Psychoneuroendocrinology. 1987;Guilford Press, New York.
131. Newton AC (1995): Protein kinase C: Structure, function and regulation. J Biol Chem 270:28495-24898.
132. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
133. O'Brian C.A., Housey G.M., Weinstein I.B. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res. 48:1988;3626-3629.
134. Oda T., Sherman M.S., Nishizuka Y. Synaptosomal protein kinase C subspecies B. Down-regulation promoted by phorbol ester and its effect on evoked norepinephrine release . J Neurochem. 56:1991;1263-1269.
135. Olds J.L., Anderson M.L., McPhie D.L., Olton D., Mishkin M., Alkon D.L. Imaging of memory-specific changes in the distribution of protein kinase C in the hippocampus. Science. 245:1989;866-869.
136. Olds J.L., Golski S., McPhie D.L., Staten L.D., Alkon D.L. Discrimination learning alters the distribution of protein kinase C in the hippocampus of rats. J Neurosci. 10:1990;3707-3713.
137. Ouimet C.C., Wang J.K.T., Walaas S.I., et al. Localization of the MARCKS (87 kDa) protein, a major specific substrate for the protein kinase C, in rat Brian. J Neurosci. 10:1990;1683-1698.
138. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochemistry. 69:1997;2336-2344.
139. Pandey G.N., Dwivedi Y., Pandey S.C., Conley R.R., Roberts R.C., Tamminga C.A. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett. 228:1997;111-114.
140. Pandey G.N., Dwivedi Y., Kumari R., Janicak P.G. Protein kinase C in platelets of depressed patients. Biol Psychiatry. 44:1998;909-911.
141. Patishi Y., Bersudsky Y., Belmaker R.H. Phorbol ester intracerebroventricularly induces a behavioral hypoactivity that is not affected by chronic or acute lithium. Eur Neuropsychopharmacol. 6:1996;39-41.
142. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
143. Pontremoli S., Mishetti M., Melloni M., Sparatore B., Salamino F., Horecker B.L. Identification of the proteolytically activated form of protein kinase C in stimulated human neutrophils. Proc Natl Acad Sci USA. 87:1990;3705-3707.
144. Post R.M., Weiss S.R., Chuang D.M. Mechanisms of action of anti-convulsants in affective disorders comparisons with lithium . J Clin Psychopharmacol. 12:1992;42S-52S.
145. Post RM, Weiss SR, Clark M, Chuang DM, Hough C, Li H (in press): Lithium, Carbamazepine, and Valproate. In: Manji HK, Bowden CL, Belmaker RH, editors. Affective Illness: Biochemical and Neurobiological Mechanisms in Bipolar Medications: Mechanisms of Action. Washington, DC: American Psychiatric Press.
146. Rana R.S., Hokin L.E. Role of Phosphoinositides in Transmembrane Signaling. Physiol Rev. 70:1990;115-164.
147. Reifman A., Wyatt R.J. Lithium A brake in the rising cost of mental illness . Arch Gen Psychiatry. 37:1980;385-388.
148. Reisine T., Zatz M. Interactions between lithium, calcium, diacylglycerides and phorbol esters in the regulation of ACTH release from AtT-20 cells. J Neurochem. 49:1987;884-889.
149. Risby E.D., Hsiao J.K., Manji H.K., et al. The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry. 48:1991;513-524.
150. Robinson P.J. The role of protein kinase C and its neuronal substrates dephosphin. B-50, and MARCKS in neurotransmitter release. Mol Neurobiol. 5:1991;87-130.
151. Rogawski M.A., Porter R.J. Antiepileptic drugs Pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds . Pharmacol Rev. 42:1990;223-286.
152. Rohlff C., Blagosklonny M.V., Kyle E., Kesari A., Kim I.Y., Zelner D.J., Hakim F., Trepel J., Bergan R.C. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate. 37:1998;51-59.
153. Rosen A., Keenan K.F., Thelen M., Nairn A.C., Aderem A. Activation of protein kinase C results in the displacement of its myristoylated, alanine-rich substrate from punctuate structures in macrophage filopodia. J Exp Med. 172:1990;1211-1215.
154. Ross E.M. Signal sorting and amplification through G protein-coupled receptors. Neuron. 3:1989;141-152.
155. Schou M. Lithium research at the Psychopharmacology Research Unit, Risskov, Denmark A historical account . Schou M., Stromgren E. Origin, Prevention and Treatment of Affective Disorders. 1979;1-8 Academic Press, London.
156. Schou M. Clinical aspects of lithium in psychiatry. Birch N.J. Lithium and the Cell. 1991;1-6 Academic Press, London.
157. Seykora J.T., Ravetch J.V., Aderem A. Cloning and molecular characterization of the murine macrophage "68-kDa" protein kinase C substrate and its regulation by bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 88:1991;2505-2509.
158. Sheng M., Greenberg M.E. The regulation and function c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
159. Siafaka-Kapadai A., Patiris M., Bowden C., Javors M. Incorporation of [3H]valproic acid into lipids in GT1-7 neurons. Biochem Pharmacol. 56:1998;207-212.
160. Sillence D., Downes C.P. Lithium treatment of affective disorders, effects of lithium on the inositol phospholipid and cyclic AMP signaling pathways. Biochem Biophys Acta. 1138:1992;46-52.
161. Small J.G., Klapper M.H., Milstein V., et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry. 48:1991;915-921.
162. Song L., Jope R. Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions. J Neurochem. 58:1992;2200-2206.
163. Stabel S., Parker P.J. Protein kinase C. Pharmacol Ther. 51:1991;71-95.
164. Stambolic V., Laurent R., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 6:1996;1664-1668.
165. Steketee J.D. Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine behavioral and in vivo microdialysis studies . Neuropharmacology. 32:1993;1289-1297.
166. Steketee J.D. Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport. 30:1994;6:69-6:72.
167. Stubbs E.B., Agranoff B.W. Lithium enhances muscarinic receptor-stimulated CDP-diacylglycerol formation in inositol-depleted SK-N-SH neuroblastoma cells. J Neurochem. 60:1993;1292-1299.
168. Suppes T., Baldessarini R.J., Faedda G.L., et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 48:1991;1082-1088.
169. Swierczynski S.L., Blackshear P.J. Membrane association of the myristoylated alanine-rick C kinase substrate (MARCKS) protein. Mutational analysis provides evidence for complex interactions. J Biol Chem. 270:1995;13436-13445.
170. Taylor C.W. The role of G proteins in transmembrane signaling. Biochem J. 272:1990;1-13.
171. Tondo L., Jamison K.R., Baldessarini R.J. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci. 836:1997;339-351.
172. Ur E., Turner T.H., Goodwin T.J., Grossman A., Besser G.M. Mania in association with hydrocortisone replacement for Addison's disease. Postgrad Med J. 68:1992;41-43.
173. 3 pituitary cells. Mol Pharmacol. 4:1992;671-678.
174. Vestergaard P., Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord. 21:1991;33-38.
175. Wagner U., Utton M., Gallo J.M., Miller C.C.J. Cellular phosphorylation of tau by GSK-3beta influences tau binding to microtubules and microtubule organization. J Cell Sci. 109:1996;1537-1543.
176. Wang H., Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry. 40:1996;568-575.
177. Wang H.Y., Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berlin). 99:1989;213-218.
178. Wang H.Y., Markowitz P., Levinson D., Undie A.S., Friedman E. Increased membrane associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiatric Res. 33:1999;171-179.
179. Wang J.F., Young L.T., Li P.P., Warsh J.J. Signal transduction abnormalities in bipolar disorder. Young L.T., Joffe R.T. Bipolar Disorder Biological Models and Their Clinical Applications . 1997;41-79 Marcel Dekker, New York.
180. Wang J.K.T., Walaas S.I., Sihra T.S., Aderem A., Greengard P. Phosphorylation and associated translocation of the 87-kDa protein, a major protein kinase C substrate, in isolated nerve terminals. Proc Natl Acad Sci USA. 86:1989;2253-2256.
181. Watson D.G., Lenox R.H. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells Potentiation by muscarinic receptor activation . J Neurochem. 67:1996;767-777.
182. Watson D.G., Wainer B.H., Lenox R.H. Phorbol ester- and retinoic acid-induced regulation of the protein kinase C substrate MARCKS in immortalized hippocampal cells. J Neurochem. 63:1994;1666-1674.
183. Watson D.G., Watterson J.M., Lenox R.H. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells. A property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther. 285:1998;307-316.
184. Wehr T.A., Goodwin F.K. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 144:1987;1403-1411.
185. Weiss S.R., Post R.M. Caveats in the use of the kindling model of affective disorders. Toxicol Ind Health. 10:(4-5):1994;421-447.
186. Wyatt R.J., Henter I. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol. 30:1995;213-219.
187. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. Genes Dev. 10:1996;1443-1454.
188. Young S., Parker P.J., Ullrich A., Stabel S. Down-regulation of Protein kinase C is due to an increased rate of degradation. Biochem J. 24:1987;775-779.
189. Yuan P.X., Chen G., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol Brain Res. 58:1998;225-230.
190. 2-terminal kinases (JNKs) in vitro and in the CNS in vivo. J Neurochem.
191. Zatz M., Reisine T.D. Lithium induces corticotropin secretion and de-sensitization in cultured anterior pituitary cells. Proc Natl Acad Sci USA. 82:1985;1286-1290.
192. Zhang L., Elmer L.W., Little K.Y. Expression and regulation of the human dopamine transporter in a neuronal cell line. Brain Res Mol Brain Res. 59:1998;66-73.